South Korean AI company Neurophet has entered a memorandum of understanding (MoU) with the Alzheimer's Network for Treatment ...
Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key ...
On 20 March, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological ...
Please provide your email address to receive an email when new articles are posted on . Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a ...
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other ...
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from ...
NEWBERRY, S.C. (WCSC) - The July heat isn’t stopping hundreds of cyclists from pedaling from one side of South Carolina to the other over the next three days. Their goal is to support those fighting ...
An experimental pill could slow memory loss and brain shrinkage in some Alzheimer’s patients, new research suggests. The pill, called ALZ-801 (valiltramiprosate), was shown to be effective in people ...
ALZ-NET is the first network developed specifically for new FDA-approved Alzheimer's treatments, collecting real-world evidence on drug effectiveness and side effects over a long period of time. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results